Terminal · Institutions

Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.

Octagon Capital Advisors LP 13F Holdings -- Portfolio & Top Positions (2026-03-31)

Octagon Capital Advisors LP (CIK 1839435) reported $903.6M across 25 reported positions in its SEC 13F filing for 2026-03-31. Largest positions: DNTH ($163.4M, 18.08%), COGT ($90.5M, 10.01%), ABVX ($75.4M, 8.34%), ALMS ($62.4M, 6.90%), ($46.1M, 5.10%). Source: SEC Form 13F.

RankTickerCompanyValue% PortfolioSharesAction
1DNTHDIANTHUS THERAPEUTICS INC$163.4M18.08%1.9MTrimmed
2COGTCOGENT BIOSCIENCES INC$90.5M10.01%2.4MHold
3ABVXABIVAX SA$75.4M8.34%677,000Trimmed
4ALMSALUMIS INC$62.4M6.90%2.8MAdded
5DEFINIUM THERAPEUTICS INC$46.1M5.10%2.4MNew
6AVBPARRIVENT BIOPHARMA INC$45.5M5.03%2.0MHold
7TSHATAYSHA GENE THERAPIES INC$39.6M4.38%8.9MHold
8KYMRKYMERA THERAPEUTICS INC$35.4M3.92%425,000Trimmed
9MIRMMIRUM PHARMACEUTICALS INC$31.3M3.46%338,900New
10BIOABIOAGE LABS INC$30.6M3.38%1.7MAdded
11CNTACENTESSA PHARMACEUTICALS PLC$29.8M3.30%750,000Hold
12KALVKALVISTA PHARMACEUTICALS INC$29.2M3.23%1.4MAdded
13XENEXENON PHARMACEUTICALS INC$28.5M3.15%490,000New
14TERNTERNS PHARMACEUTICALS INC$27.9M3.09%530,000New
15OCULOCULAR THERAPEUTIX INC$26.8M2.97%3.2MAdded
16PALIPALISADE BIO INC$18.0M1.99%10.3MAdded
17TRVITREVI THERAPEUTICS INC$17.7M1.96%1.5MTrimmed
18IRONDISC MEDICINE INC$17.3M1.91%270,000New
19AKTIS ONCOLOGY INC$17.2M1.90%960,847New
20CNTXCONTEXT THERAPEUTICS INC$13.8M1.52%5.2MNew
21DTILPRECISION BIOSCIENCES INC$12.3M1.36%2.2MAdded
22DBVTDBV TECHNOLOGIES S A$12.0M1.33%574,200Hold
23UNCYUNICYCIVE THERAPEUTICS INC$6.6M0.73%1.0MHold
24BRIDGEBIO ONCOLOGY THERAPEUT$6.4M0.71%719,000Trimmed
25LXEOLEXEO THERAPEUTICS INC$6.3M0.70%1.1MTrimmed

Source: SEC Form 13F filings · as of 2026-03-31